Literature DB >> 25857733

Development and evaluation of murine lung-specific disease models for Pseudomonas aeruginosa applicable to therapeutic testing.

Matthew B Lawrenz1, Ashley E Biller2, Daniel E Cramer2, Jennifer L Kraenzle2, Julie B Sotsky2, Carol D Vanover2, Deborah R Yoder-Himes3, Angela Pollard4, Jonathan M Warawa5.   

Abstract

Pseudomonas aeruginosa is an opportunistic bacterial pathogen capable of causing a wide range of disease manifestations, including severe bacterial pneumonia. Recently, clinics have reported a rise in nosocomial infections with multidrug resistant (MDR) species, including MDR strains of P. aeruginosa. In order to quickly evaluate the efficacy of new therapeutics for MDR infections, highly reproducible and validated animal models need to be developed for pre-clinical testing. Here, we describe the characterization of two murine models to study MDR P. aeruginosa respiratory disease. We evaluated and compared these models using a non-invasive intratracheal instillation method and established the 50% lethal dose, course of infection, biometric parameters of disease and degree of pneumonia development for each model. Further, we tested meropenem as a proof-of-concept therapeutic and report efficacy data that suggests that the leukopenic model could serve a robust pre-clinical model to test novel therapeutics. © FEMS 2015. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  MDR Pseudomonas aeruginosa; biometric endpoint criteria; intubation-mediated intratracheal (IMIT) inoculation; murine respiratory disease; therapeutic model

Mesh:

Substances:

Year:  2015        PMID: 25857733      PMCID: PMC4849349          DOI: 10.1093/femspd/ftv025

Source DB:  PubMed          Journal:  Pathog Dis        ISSN: 2049-632X            Impact factor:   3.166


  19 in total

1.  Bacteria subsisting on antibiotics.

Authors:  Gautam Dantas; Morten O A Sommer; Rantimi D Oluwasegun; George M Church
Journal:  Science       Date:  2008-04-04       Impact factor: 47.728

2.  Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen.

Authors:  C K Stover; X Q Pham; A L Erwin; S D Mizoguchi; P Warrener; M J Hickey; F S Brinkman; W O Hufnagle; D J Kowalik; M Lagrou; R L Garber; L Goltry; E Tolentino; S Westbrock-Wadman; Y Yuan; L L Brody; S N Coulter; K R Folger; A Kas; K Larbig; R Lim; K Smith; D Spencer; G K Wong; Z Wu; I T Paulsen; J Reizer; M H Saier; R E Hancock; S Lory; M V Olson
Journal:  Nature       Date:  2000-08-31       Impact factor: 49.962

3.  Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents.

Authors:  Y Carmeli; N Troillet; G M Eliopoulos; M H Samore
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

4.  Bactericidal activity of various antibiotics against biofilm-producing Pseudomonas aeruginosa.

Authors:  A Abdi-Ali; M Mohammadi-Mehr; Y Agha Alaei
Journal:  Int J Antimicrob Agents       Date:  2006-02-03       Impact factor: 5.283

5.  Incidence of multidrug resistant pseudomonas aeruginosa isolated from burn patients and environment of teaching institution.

Authors:  Indu Biswal; Balvinder Singh Arora; Dimple Kasana
Journal:  J Clin Diagn Res       Date:  2014-05-15

6.  Pseudomonas pneumonia in infants: an autopsy study.

Authors:  Sonia L Bonifacio; Joseph A Kitterman; Philip C Ursell
Journal:  Hum Pathol       Date:  2003-09       Impact factor: 3.466

7.  Dose translation from animal to human studies revisited.

Authors:  Shannon Reagan-Shaw; Minakshi Nihal; Nihal Ahmad
Journal:  FASEB J       Date:  2007-10-17       Impact factor: 5.191

8.  Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalized in intensive care units in United States and European hospitals (2009-2011).

Authors:  Helio S Sader; David J Farrell; Robert K Flamm; Ronald N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  2013-12-06       Impact factor: 2.803

9.  The extracellular matrix protects Pseudomonas aeruginosa biofilms by limiting the penetration of tobramycin.

Authors:  Boo Shan Tseng; Wei Zhang; Joe J Harrison; Tam P Quach; Jisun Lee Song; Jon Penterman; Pradeep K Singh; David L Chopp; Aaron I Packman; Matthew R Parsek
Journal:  Environ Microbiol       Date:  2013-06-10       Impact factor: 5.491

10.  ExoY, an adenylate cyclase secreted by the Pseudomonas aeruginosa type III system.

Authors:  T L Yahr; A J Vallis; M K Hancock; J T Barbieri; D W Frank
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-10       Impact factor: 11.205

View more
  4 in total

Review 1.  FDA Public Workshop Summary: Advancing Animal Models for Antibacterial Drug Development.

Authors:  James M Byrne; Ursula Waack; Edward A Weinstein; Abhay Joshi; Simone M Shurland; Dmitri Iarikov; Jürgen B Bulitta; Binh An Diep; Tina Guina; William W Hope; Matthew B Lawrenz; Alexander J Lepak; Brian M Luna; Lynn Miesel; Andrew J Phipps; Thomas J Walsh; William Weiss; Thushi Amini; John J Farley
Journal:  Antimicrob Agents Chemother       Date:  2020-12-16       Impact factor: 5.191

2.  Recombinant Human Plasma Gelsolin Improves Survival and Attenuates Lung Injury in a Murine Model of Multidrug-Resistant Pseudomonas aeruginosa Pneumonia.

Authors:  Mark J DiNubile; Susan L Levinson; Thomas P Stossel; Matthew B Lawrenz; Jonathan M Warawa
Journal:  Open Forum Infect Dis       Date:  2020-06-19       Impact factor: 3.835

3.  Clinically relevant model of pneumococcal pneumonia, ARDS, and nonpulmonary organ dysfunction in mice.

Authors:  Jeffrey E Gotts; Olivier Bernard; Lauren Chun; Roxanne H Croze; James T Ross; Nicolas Nesseler; Xueling Wu; Jason Abbott; Xiaohui Fang; Carolyn S Calfee; Michael A Matthay
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2019-09-11       Impact factor: 5.464

4.  Novel Synthesis of Kanamycin Conjugated Gold Nanoparticles with Potent Antibacterial Activity.

Authors:  Jason N Payne; Hitesh K Waghwani; Michael G Connor; William Hamilton; Sarah Tockstein; Harsh Moolani; Fenil Chavda; Vivek Badwaik; Matthew B Lawrenz; Rajalingam Dakshinamurthy
Journal:  Front Microbiol       Date:  2016-05-02       Impact factor: 5.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.